Should You Buy Palantir Stock Before the Huge Investor Update? | PLTR Stock Analysis
Summary
Parkev analyzes Palantir's stock performance and fundamentals, noting that the business is flourishing with total revenue accelerating to $1.9 billion. Parkev highlights that the U.S. commercial segment is particularly strong, showing a 149% revenue growth in the most recent quarter. Parkev emphasizes Palantir's pristine balance sheet, which features $9.2 billion in cash and short-term investments with zero debt, alongside an impressive operating margin of 47%.
Parkev evaluates Palantir's valuation using a forward P/E ratio and a discounted cash flow model. Parkev states that the current forward P/E of 85 is fair given the business's maturity and growth, but Parkev warns that any valuation exceeding a P/E of 100 would be considered too expensive. Through a detailed DCF model, Parkev calculates a fair value of $192 per share, which is slightly lower than the market price of $199 at the time of recording. Parkev personally maintains a position with an average cost of $106 but does not intend to add more at current prices.
Parkev advises against buying Palantir stock immediately before the upcoming quarterly results on November 2, 2026. Parkev argues that because the stock is not undervalued and the risks are tilted to the downside, it is safer to wait for the management's updated outlook and full financial data. Parkev intends to remain patient and will not make any personal trades until after the earnings information has been processed.
Mentioned Stocks
Reasoning: Parkev explains that while Palantir's fundamentals are excellent—with 149% U.S. commercial revenue growth and a strong cash position—the stock is no longer undervalued at $199. Parkev calculates a fair value of $192 per share and warns that a forward P/E ratio above 100 would be too expensive to buy. Parkev advises against purchasing shares before the upcoming November 2, 2026, earnings release, suggesting there is more downside risk than upside potential at current levels. Parkev notes that previous buy recommendations were made when the stock was below $110, and Parkev's own average cost basis is $106.